Market research
5XS2.F LexaGene Holdings Inc
F EUR Healthcare
Latest close
Latest stored close unavailable
Test a moving-average rule with historical data.
Market facts
- Market cap
- 11M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- 2.26
Profile
Instrument facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- CA52886L1031
- Market cap
- 11M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- 0.0%
- Beta
- 2.26
About
About LexaGene Holdings Inc
LexaGene Holdings Inc., a biotechnology company, engages in the research, development, and commercialization of pathogen detection systems. It offers MiQLab, an automated pathogen detection system that aims to transform pathogen detection in veterinary diagnostics, human clinical diagnostics, food and water safety testing, and other life sciences markets; and assay panels. Its automated pathogen detection platform is used at the site of sample collection, which offers unprecedented ease-of-use, sensitivity, and breadth of pathogen detection. LexaGene Holdings Inc. was incorporated in 2007 and is headquartered in Beverly, Massachusetts.
Research context
LexaGene Holdings Inc appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Medical Devices
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the 5XS2.F discussion.
5 years, 7 months ago
LexaGene Holdings Inc is currently in a long term downtrend where the price is trading 22.0% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
LexaGene Holdings Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 17.8% to $-3M since the same quarter in the previous year.
Finally, its free cash flow fell by 74.6% to $-3M since the same quarter in the previous year.
Based on the above factors, LexaGene Holdings Inc gets an overall score of 1/5.